Imatinib & Combo Chemo in Treating Pts w/newly diagnosed Ph+ ALL
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
-
Clinical Trial Information
Trial Contact: Doyle, Katherine M; Dubberly, Paige D; Parker, Melanie; Armatti, Julie M; Spinelli, Jennifer
Trial Phone: 3218412008 ; 321-841-7561 ; 321-843-1036 ; 321-843-5284 ; 321.841.5357
-
IRB No: AALL1631
Protocol Abbrev: AALL1631
Principal Investigator: Amy A. Smith, MD
Phase: Drug: Phase III
Age Group: Pediatric
Secondary Protocol No: AALL1631
Treatment: Current EsPhALL chemotherapy backbone + imatinib, COG HR chemotherapy backbone + imatinib
Therapies Involved: Chemotherapy
ClinicalTrials.gov ID: NCT03007147
-
Objective
This randomized phase III trial studies how well imatinib mesylate and combination chemotherapy work in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving imatinib mesylate and combination chemotherapy may work better in treating patients with Philadelphia chromosome positive acute lymphoblastic leukemia.
-
Key Eligibility
Inclusion Criteria:
• Patients who have not previously enrolled on AALL08B1 or APEC14B1 (if open for classification of newly diagnosed ALL patients) prior to enrollment on AALL1631, a baseline diagnostic sample must be available to develop an MRD probe
• Newly diagnosed de novo ALL (B-ALL or T-ALL) with definitive evidence of BCR-ABL1 fusion by karyotype, fluorescence in situ hybridization (FISH) and/or reverse transcriptase (RT)-PCR
◦For patients who DO NOT enter AALL1631 via AALL08B1 or APEC14B1 (if open for classification of newly diagnosed ALL patients), laboratory reports detailing evidence of BCR-ABL1 fusion must be submitted for rapid central review within 72 hours of study enrollment
◦Patients with known chronic myelogenous leukemia (CML) who develop lymphoid blast crisis are not eligible
• Patient must have previously started induction therapy, which includes vincristine, a corticosteroid, pegaspargase, with or without anthracycline, and/or other standard cytotoxic chemotherapy
• Patient has not received more than 14 days of induction therapy
• Patient has not had prior treatment with imatinib, dasatinib, or any other BCR-ABL1 inhibitor
• Karnofsky/Lansky performance status >= 60; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age
• Direct bilirubin =< 2.0 mg/dL
• Shortening fraction of >= 27% by echocardiogram
• Ejection fraction of >= 50% by radionuclide angiogram or echocardiogram
• Corrected QT interval, QTc < 480 msec
◦Note: Repeat echocardiogram is not required if echocardiogram was obtained within 21 days of study enrollment
• Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2
• Serum creatinine within normal limits based on age/gender, as follows:
◦1 to < 2 years: maximum serum creatinine 0.6 mg/dL (both male and female)
◦2 to < 6 years: maximum serum creatinine 0.8 mg/dL (both male and female)
◦6 to < 10 years: maximum serum creatinine 1 mg/dL (both male and female)
◦10 to < 13 years: maximum serum creatinine 1.2 mg/dL (both male and female)
◦13 to < 16 years: maximum serum creatinine 1.5 mg/dL (male), 1.4 mg/dL (female)
◦>= 16 years: maximum serum creatinine 1.7 mg/dL (male), 1.4 mg/dL (female)
Exclusion Criteria:
• Known history of chronic myelogenous leukemia (CML)
• ALL developing after a previous cancer treated with cytotoxic chemotherapy
• Active, uncontrolled infection, or active systemic illness that requires ongoing vasopressor support or mechanical ventilation
• Down syndrome
• Pregnancy and breast feeding
◦Female patients who are pregnant; a pregnancy test is required for female patients of childbearing potential
◦Lactating females who plan to breastfeed their infants
◦Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation
• Patients with congenital long QT syndrome, history of ventricular arrhythmias or heart block
• All patients and/or their parents or legal guardians must sign a written informed consent
• All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
